A Phase IIIb/IV, Multicenter, Randomized, Open-Label, Two-Arm Study to Investigate the Efficacy, Safety, and Durability of Faricimab Administered up to Every 24 Weeks in Patients With Neovascular Age-Related Macular Degeneration
Latest Information Update: 04 Nov 2026
At a glance
- Drugs Faricimab (Primary)
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms CONSTANCE
- Sponsors Roche
Most Recent Events
- 31 Jul 2026 Planned End Date changed from 16 Sep 2027 to 20 Sep 2027.
- 31 Jul 2026 Planned primary completion date changed from 15 Oct 2026 to 20 Oct 2026.
- 03 Nov 2025 Planned End Date changed from 31 Jan 2028 to 16 Sep 2027.